NKGN Stock Overview
Operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
NKGen Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.35 |
| 52 Week High | US$4.06 |
| 52 Week Low | US$0.20 |
| Beta | 0.52 |
| 11 Month Change | -12.32% |
| 3 Month Change | -55.45% |
| 1 Year Change | -88.05% |
| 33 Year Change | -96.39% |
| 5 Year Change | n/a |
| Change since IPO | -96.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| NKGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 32.6% | 2.5% | 2.2% |
| 1Y | -88.1% | 16.1% | 31.6% |
Return vs Industry: NKGN underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: NKGN underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| NKGN volatility | |
|---|---|
| NKGN Average Weekly Movement | 48.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NKGN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NKGN's weekly volatility has increased from 34% to 49% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 63 | Paul Y. Song | nkgenbiotech.com |
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX.
NKGen Biotech, Inc. Fundamentals Summary
| NKGN fundamental statistics | |
|---|---|
| Market cap | US$12.61m |
| Earnings (TTM) | -US$88.25m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs NKGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NKGN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$88.25m |
| Earnings | -US$88.25m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -39.6% |
How did NKGN perform over the long term?
See historical performance and comparison